GSK Advances mRNA Flu Vaccine Development with Promising Results

GSK has announced promising results for its mRNA flu vaccine, showing positive immune responses in both younger and older adults. The vaccine will now advance to late-stage clinical development, aiming to provide enhanced protection against flu.

The phase 2 study evaluated different doses of the multivalent mRNA vaccine against approved flu vaccines in 250 healthy adults aged 18-64 and 250 healthy older adults aged 65-85. According to GSK, the vaccine resulted in robust immune responses to both influenza A and B strains, surpassing standard care. Tony Wood, GSK’s Chief Scientific Officer, highlighted the significance of these results, indicating a critical step forward for the company’s mRNA program.

The vaccine leverages second-generation mRNA technology and is backed by the GSK-CureVac infectious disease partnership. This has demonstrated an acceptable safety and reactogenicity profile across all tested formulations, reinforcing its potential as a leading flu vaccine.

The continued collaboration of the partners aim to develop world class vaccines, with GSK recently gaining full control over development and manufacturing through a new licensing agreement. CureVac’s Chief Scientific Officer, expressed enthusiasm about the promising immune responses, especially against influenza B strains.

The positive phase 2 results drives GSK’s mRNA flu vaccine toward late-stage development, positioning it as a potential ground-breaking solution for seasonal influenza. This advancement, combined with GSK’s recent successes in other therapeutic areas like severe asthma, underscores the company’s commitment to innovation in infectious disease prevention.

For the latest updates and in-depth insights into the world of Pharmaceuticals, including breakthrough treatments, industry trends, and regulatory news, contact Alex Martin today!